Competition-based domain allocation

Target: MAPT Composite Score: 0.650 Price: $0.50 Citation Quality: 60% neurodegeneration Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
✓ All Quality Gates Passed
Quality Report Card click to collapse
B
Composite: 0.650
Top 36% of 1402 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
B+ Mech. Plausibility 15% 0.70 Top 39%
B Evidence Strength 15% 0.65 Top 35%
B Novelty 12% 0.65 Top 63%
B Feasibility 12% 0.65 Top 38%
F Impact 12% 0.00 Top 50%
F Druggability 10% 0.00 Top 50%
F Safety Profile 8% 0.00 Top 50%
F Competition 6% 0.00 Top 50%
F Data Availability 5% 0.00 Top 50%
F Reproducibility 5% 0.00 Top 50%
Evidence
6 supporting | 0 opposing
Citation quality: 0%
Debates
1 session B+
Avg quality: 0.72
Convergence
0.00 F 20 related hypothesis share this target

Hypotheses from Same Analysis (3)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

Tau dysfunction destabilizes labile pool
Score: 0.750 | Target: MAPT
Domain boundary cross-talk hypothesis
Score: 0.600 | Target: MAP6
Neuronal-specific domain stabilization
Score: 0.550 | Target: ANK2

Description

Tau and MAP6 compete for microtubule binding sites in a concentration-dependent manner, with relative local abundance determining domain stability

Prediction: Artificially equalizing tau:MAP6 ratio on individual microtubules will produce intermediate stability domains with mixed molecular signatures

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["MAPT/Tau Protein
Microtubule Stabilizer"] B["CDK5/GSK3B Activation
Kinase Dysregulation"] C["Tau Hyperphosphorylation
Ser396/Thr231/Ser202"] D["Tau Detachment
Microtubule Destabilized"] E["Tau Oligomers
Paired Helical Filaments"] F["Neurofibrillary Tangles
Intraneuronal Inclusions"] G["Axonal Transport Failure
Synaptic Dysfunction"] H["Neurodegeneration
Tauopathy Spread"] A --> B B --> C C --> D D --> E E --> F D --> G G --> H F --> H style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style C fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.70 (15%) Evidence 0.65 (15%) Novelty 0.65 (12%) Feasibility 0.65 (12%) Impact 0.00 (12%) Druggability 0.00 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.00 (5%) KG Connect 0.50 (8%) 0.650 composite
6 citations 5 with PMID 5 medium Validation: 0% 6 supporting / 0 opposing
For (6)
5
No opposing evidence
(0) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
1
2
MECH 3CLIN 1GENE 2EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Antagonistic roles of tau and MAP6 in regulating n…SupportingGENEJ Cell Sci MEDIUM2024-PMID:39257379-
Tau filaments with the Alzheimer fold in human MAP…SupportingMECHNat Struct Mol … MEDIUM2025-PMID:40044789-
MAPT mutations, tauopathy, and mechanisms of neuro…SupportingGENELab Invest MEDIUM2019-PMID:30742061-
Endolysosomal impairment by binding of amyloid bet…SupportingMECHAutophagy MEDIUM2023-PMID:36843263-
Tau-targeting antisense oligonucleotide MAPT(Rx) i…SupportingCLINNat Med MEDIUM2023-PMID:37095250-
Tau and MAP6 compete for microtubule binding sites…SupportingMECH------
Legacy Card View — expandable citation cards

Supporting Evidence 6

Tau and MAP6 compete for microtubule binding sites in a concentration-dependent manner, with relative local ab…
Tau and MAP6 compete for microtubule binding sites in a concentration-dependent manner, with relative local abundance determining domain stability
Antagonistic roles of tau and MAP6 in regulating neuronal development. MEDIUM
J Cell Sci · 2024 · PMID:39257379
Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W. MEDIUM
Nat Struct Mol Biol · 2025 · PMID:40044789
MAPT mutations, tauopathy, and mechanisms of neurodegeneration. MEDIUM
Lab Invest · 2019 · PMID:30742061
Endolysosomal impairment by binding of amyloid beta or MAPT/Tau to V-ATPase and rescue via the HYAL-CD44 axis … MEDIUM
Endolysosomal impairment by binding of amyloid beta or MAPT/Tau to V-ATPase and rescue via the HYAL-CD44 axis in Alzheimer disease.
Autophagy · 2023 · PMID:36843263
Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-… MEDIUM
Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Nat Med · 2023 · PMID:37095250

Opposing Evidence 0

No evidence recorded
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Artifact Review | 4 rounds | 2026-04-25 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Evaluation: Tau and MAP6 Establish Labile and Stable Domains on Microtubules

Key Scientific Contributions

1. Paradigm Shift: MAPs Create Rather Than Recognize Microtubule Domains


The paper's central finding challenges the prevailing view that MAPs passively bind to pre-existing stable or labile microtubule domains. Instead, tau and MAP6 actively establish these functional domains. This fundamentally reconceptualizes how the axonal cytoskeleton is organized—microtubule dynamics are not a pre-determined structural feature but are actively sculpted by MAP interactions.

2. Demo

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Critical Evaluation: Tau and MAP6 Establish Labile and Stable Domains on Microtubules

Methodological Weaknesses

1. Non-Physiological Cell Model


The mechanistic evidence primarily derives from RFL-6 fibroblasts ectopically expressing fluorescent tau and MAP6. Fibroblasts lack neurons' specialized microtubule architecture (no axon initial segment, no organelle transport machinery, different tubulin isotype expression). Ectopic overexpression also bypasses endogenous regulatory mechanisms—transport to specific microtubule subpopulations, activity-dependent modulation, and cell-type

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

Expert Assessment: Tau and MAP6 Establish Labile and Stable Domains on Microtubules

1. Novelty Rating: 7/10

The paper's core claim—that MAPs actively establish functional microtubule domains rather than passively binding to pre-existing ones—represents a meaningful conceptual advance. This paradigm shift moves beyond the prevailing "recognition" model in cytoskeletal biology. However, the novelty is tempered by:

  • Extensive prior literature on MAP-microtubule interactions (tau studied since the 1970s)
  • MAP6's known stability-promoting functions already established
  • The fundamenta

Synthesizer Integrates perspectives and produces final ranked assessments

{"summary":"This paper demonstrates that tau and MAP6 actively establish rather than merely bind to labile and stable domains on microtubules. Using RFL-6 fibroblasts ectopically expressing fluorescent MAPs, the authors show that tau-rich domains become more labile while MAP6-rich domains become more stable, with these MAPs segregating to distinct domains on either different microtubules or different regions of the same microtubule. Computational modeling validates this mechanistic framework, while corroborative data from both juvenile and adult rodent axons confirms the in vivo relevance of t

Price History

0.640.650.66 0.67 0.63 2026-04-252026-04-252026-04-25 Market PriceScoreevidencedebate 1 events
7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
1

Clinical Trials (0) Relevance: 75%

No clinical trials data available

📚 Cited Papers (5)

MAPT mutations, tauopathy, and mechanisms of neurodegeneration.
Laboratory investigation; a journal of technical methods and pathology (2019) · PMID:30742061
No extracted figures yet
Endolysosomal impairment by binding of amyloid beta or MAPT/Tau to V-ATPase and rescue via the HYAL-CD44 axis in Alzheimer disease.
Autophagy (2023) · PMID:36843263
No extracted figures yet
Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Nature medicine (2023) · PMID:37095250
No extracted figures yet
Antagonistic roles of tau and MAP6 in regulating neuronal development.
J Cell Sci (2024) · PMID:39257379
No extracted figures yet
Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W.
Nature structural & molecular biology (2025) · PMID:40044789
No extracted figures yet

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score
0.50
31.7th percentile (747 hypotheses)
Tokens Used
0
KG Edges Generated
0
Citations Produced
6

Cost Ratios

Cost per KG Edge
0.00 tokens
Lower is better (baseline: 2000)
Cost per Citation
0.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
0.00 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.050
10% weight of efficiency score
Adjusted Composite
0.700

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Related Hypotheses

Glymphatic-Mediated Tau Clearance Dysfunction
Score: 0.821 | neuroscience
Excitatory Neuron Synaptic Dysfunction and Mitochondrial Stress via MAPT (tau)
Score: 0.790 | neurodegeneration
Dual-Circuit Tau Vulnerability Cascade
Score: 0.754 | neuroscience
Tau dysfunction destabilizes labile pool
Score: 0.750 | neurodegeneration
Tau/MAP6 ratio as a master switch for microtubule dynamics plasticity
Score: 0.750 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified
IF we reconstitute individual microtubules in vitro with purified tau and MAP6 at defined stoichiometric ratios (e.g., 1:1, 2:1, 1:2) while holding total protein concentration constant, THEN the mechanical rigidity (flexural rigidity) and thermal stability (critical temperature of disassembly) will vary in a predictable, continuous gradient across the tau:MAP6 ratio range with intermediate ratios producing intermediate stability values.
pending conf: 0.45
Expected outcome: Linear or monotonic correlation between tau:MAP6 ratio and microtubule mechanical properties measured by optical tweezers or thermal denaturation, with mixed domains exhibiting heterogeneous decoration patterns on cryo-EM
Falsified by: Microtubules show discrete, non-graded stability states regardless of ratio; intermediate ratios produce phase-separated domains but no intermediate stability values; or MAP6 and tau occupy non-overlapping binding sites with no measurable competition
Method: In vitro reconstitution with purified human MAP6 and 2N4R tau isoform, single-molecule force spectroscopy, cryo-EM structural analysis, and temperature-controlled disassembly assays using established protocols
IF we apply pseudo-phosphorylated tau (using casein kinase II or GSK3β treatment at 6-8 sites) or introduce frontotemporal dementia-linked MAPT mutations (P301L, V337M) to primary cortical neurons, THEN the relative occupancy of tau versus MAP6 on axonal microtubules will shift toward increased tau decoration as measured by quantitative cryo-electron tomography and immunogold labeling.
pending conf: 0.38
Expected outcome: ≥30% increase in tau:MAP6 ratio on axonal microtubules under disease-mimicking conditions, detectable by decreased MAP6 epitope accessibility or increased tau:MAP6 gold particle ratio using stereology
Falsified by: Disease-associated tau modifications do not alter tau:MAP6 binding site competition; MAP6 expression compensates to maintain constant net occupancy; or tau and MAP6 bind non-competitively to distinct sites with no measurable displacement
Method: Primary neuronal culture from C57BL/6 mice (E16-18), AAV-mediated expression of mutant or phosphorylated tau constructs, cryo-ET with immunogold labeling, and quantitative stereology using established neurodegeneration models

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

3D Protein Structure

🧬 MAPT — PDB 5O3L Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)